Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INDV
stocks logo

INDV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
306.22M
+2.76%
0.678
+112.61%
269.53M
+1.33%
0.650
+58.54%
281.67M
-6.73%
0.707
+38.56%
Estimates Revision
The market is revising Upward the revenue expectations for Indivior PLC (INDV) for FY2025, with the revenue forecasts being adjusted by 9.85% over the past three months. During the same period, the stock price has changed by 38.51%.
Revenue Estimates for FY2025
Revise Upward
up Image
+9.85%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+35.45%
In Past 3 Month
Stock Price
Go Up
up Image
+38.51%
In Past 3 Month
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 34.600
sliders
Low
35.00
Averages
38.67
High
41.00
Current: 34.600
sliders
Low
35.00
Averages
38.67
High
41.00
Morgan Stanley
Overweight
maintain
$28 -> $36
2025-12-03
New
Reason
Morgan Stanley
Price Target
$28 -> $36
2025-12-03
New
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on Indivior to $36 from $28 and keeps an Overweight rating on the shares. The firm sees the EU Pharmaceuticals sector set up as neutral into 2026, with fundamentals intact at a low valuation premium compared to history, offset by better EPS growth elsewhere in Europe, the analyst tells investors in a year-ahead outlook note.
Northland
Outperform
upgrade
$30 -> $40
2025-10-31
Reason
Northland
Price Target
$30 -> $40
2025-10-31
upgrade
Outperform
Reason
Northland raised the firm's price target on Indivior to $40 from $30 and keeps an Outperform rating on the shares. The firm's upward revision reflects confidence in Sublocade's prospects, combined with Indivior's cost containment initiatives, the analyst tells investors.
Craig-Hallum
Buy
maintain
$34 -> $41
2025-10-31
Reason
Craig-Hallum
Price Target
$34 -> $41
2025-10-31
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Indivior to $41 from $34 and keeps a Buy rating on the shares. The firm cites the company's Q3 massive beat, delivering revenue of $314M, beating Street estimates of $261.9M, with broad-based strength from both Sublocade and Suboxone.
Piper Sandler
NULL -> Overweight
upgrade
$27 -> $41
2025-10-31
Reason
Piper Sandler
Price Target
$27 -> $41
2025-10-31
upgrade
NULL -> Overweight
Reason
Piper Sandler raised the firm's price target on Indivior to $41 from $27 and keeps an Overweight rating on the shares. The firm notes Indivior reported Q3 2025 diluted non-GAAP earnings per share of 72c on revenue of $314M, compared to Street estimates of 41c and $262M, respectively. Management is now guiding to Sublocade worldwide sales of $825M-$845M, up from the previous range of $765M-$785M, and now implying annual growth of about 10% at the midpoint.
H.C. Wainwright
Brandon Folkes
maintain
$28 -> $35
2025-10-30
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$28 -> $35
2025-10-30
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Indivior to $35 from $28 and keeps a Buy rating on the shares. The company reported a strong Q3 that exceeded expectations across all key metrics and validated the firm's positive call on the stock into the quarter, the analyst tells investors in a research note. The firm added that its revised target may still prove conservative, as it implies just 7.4x 2026 EV/EBITDA, compared to the peer group average of about 9.8x, suggesting meaningful re-rating potential as execution continues.
H.C. Wainwright
Brandon Folkes
Buy
initiated
$27
2025-08-06
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$27
2025-08-06
initiated
Buy
Reason
H.C. Wainwright analyst Brandon Folkes initiated coverage of Indivior with a Buy rating and $27 price target. The firm sees a favorable risk/reward at current share levels, saying the durability of Sublocade revenue in the growing long-acting injectable market for opioid use disorder is underappreciated. In addition, Indivior's operational focus could drive meaningful cost reduction efforts in non-core areas of the company, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Indivior PLC (INDV.O) is 12.32, compared to its 5-year average forward P/E of 12.57. For a more detailed relative valuation and DCF analysis to assess Indivior PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.57
Current PE
12.32
Overvalued PE
15.91
Undervalued PE
9.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.49
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.33
Undervalued EV/EBITDA
4.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.23
Current PS
0.00
Overvalued PS
2.87
Undervalued PS
1.59
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

INDV News & Events

Events Timeline

(ET)
2025-11-21
09:30:50
Indivior's Resolution of Legacy DOJ Issue Eliminates 'Significant Burden,' According to Northland
select
2025-11-20 (ET)
2025-11-20
16:02:06
Indivior Resolves Ongoing U.S. Department of Justice Issue
select
2025-10-01 (ET)
2025-10-01
08:15:46
Indivior plans to relocate its headquarters from the U.K. to the U.S.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-04NASDAQ.COM
The Remitly Review: Insights from Divisadero's $95 Million Exit on the Digital Currency Landscape

  • Divestment Details: Divisadero Street Capital Management, LP sold 5,036,343 shares of Remitly Global, reducing its position by approximately $94.68 million, which now accounts for only 0.04% of the fund's $2.29 billion AUM.

  • Impact on Remitly Global: The significant sell-off removes a major institutional holder, prompting investors to reassess Remitly's current market position and future profitability in the competitive digital remittance landscape.

  • Company Overview: Remitly Global specializes in digital cross-border remittance services, primarily targeting immigrant families, and aims to provide secure and efficient money transfer solutions across approximately 150 countries.

  • Market Challenges: The company faces increased competition from digital-first rivals and traditional banks, alongside high customer acquisition costs and tightening regulatory requirements, necessitating a focus on profitability and customer retention.

[object Object]
Preview
2.0
11-21Benzinga
Major Stocks Including Elastic, Veeva Systems, and HIVE Digital Decline in Friday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures rose this morning, with Dow futures increasing by approximately 200 points on Friday.

  • Elastic NV Earnings Report: Elastic NV's shares dropped 12.3% in pre-market trading despite reporting adjusted earnings of 64 cents per share, surpassing analyst expectations, and quarterly revenue of $423.48 million, which also exceeded estimates.

  • Other Stocks Declining: Several other stocks experienced declines in pre-market trading, including Luda Technology Group Ltd (-11.1%), AnaptysBio Inc (-9.7%), and Sigma Lithium Corp (-8.4%).

  • Veeva Systems Performance: Veeva Systems Inc saw a 6.7% drop in pre-market trading despite posting strong third-quarter results and raising its fiscal year earnings and revenue estimates above analyst predictions.

[object Object]
Preview
7.0
11-21PRnewswire
Indivior Concludes Legacy U.S. Department of Justice Matter

  • Indivior Resolves DOJ Matter: Indivior PLC has paid $295 million to conclude a legacy matter with the U.S. Department of Justice, terminating the resolution agreement with the DOJ.

  • CEO Statement: CEO Joe Ciaffoni expressed satisfaction with the resolution, highlighting its significance in removing a major liability and simplifying the company's capital structure.

  • Commitment to Integrity: Indivior reaffirms its commitment to conducting business with integrity and maintaining a comprehensive compliance program.

  • Focus on Opioid Use Disorder: The company aims to transform opioid use disorder from a crisis to a recognized chronic disease, with a focus on developing evidence-based treatments.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Indivior PLC (INDV) stock price today?

The current price of INDV is 34.6 USD — it has increased 1.7 % in the last trading day.

arrow icon

What is Indivior PLC (INDV)'s business?

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.

arrow icon

What is the price predicton of INDV Stock?

Wall Street analysts forecast INDV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDV is 38.67 USD with a low forecast of 35.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Indivior PLC (INDV)'s revenue for the last quarter?

Indivior PLC revenue for the last quarter amounts to 314.00M USD, increased 2.28 % YoY.

arrow icon

What is Indivior PLC (INDV)'s earnings per share (EPS) for the last quarter?

Indivior PLC. EPS for the last quarter amounts to 0.33 USD, increased 94.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Indivior PLC (INDV)'s fundamentals?

The market is revising Upward the revenue expectations for Indivior PLC (INDV) for FY2025, with the revenue forecasts being adjusted by 9.85% over the past three months. During the same period, the stock price has changed by 38.51%.
arrow icon

How many employees does Indivior PLC (INDV). have?

Indivior PLC (INDV) has 1030 emplpoyees as of December 05 2025.

arrow icon

What is Indivior PLC (INDV) market cap?

Today INDV has the market capitalization of 4.33B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free